Dr Reddy’s Laboratories (DRL) called off a deal to acquire the prescription portfolio of JB Chemicals and Pharmaceuticals in Russia owing to differences over valuation and other operational issues. Earlier in July, Dr Reddy’s Laboratories had entered in to an agreement with the Mumbai-based pharmaceutical firm to acquire 20 key prescription brands marketed by JB Chemicals in Russia and Common Wealth of Independent States (CIS) regions. The transaction involved sale of product registrations and intellectual property rights for a consideration of $35 million. The acquisition was supposed to expand Dr Reddy’s prescription, hospital and over the-counter market portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: